Health Vidya

These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI® (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of CIMERLI has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to LUCENTIS® (ranibizumab injection).